N-terminal pro-B-type natriuretic peptide as a predictor of repeat coronary revascularization

International Journal of Cardiology

Volumn 126, Issue 3, 2008, Pages 322-332

  Sir, Jung Ju ^a   Chung, Woo Young ^b   Hwang, Seok Jae ^b   Kang, Hyun Jae ^b   Cho, Young Seok ^b   Koo, Bon Kwon ^b   Chae, In Ho ^b   Choi, Dong Ju ^b   Kim, Hyo Soo ^b   Sohn, Dae Won ^b   Kim, Cheol Ho ^b   Oh, Byung Hee ^b   Park, Young Bae ^b   Choi, Yun Shik ^b  

^a Inje University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Myocardial ischemia; NT proBNP; Percutaneous coronary intervention; Restenosis; Revascularization

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE WALL MOTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETREATMENT; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 43049159139     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.04.007     Document Type: Article

References (49)

1. Minamino N., Aburaya M., Ueda S., Kangawa K., and Matsuo H. The presence of brain natriuretic peptide of 12,000 daltons in porcine heart. Biochem Biophys Res Commun 155 (1998) 740-746
2. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
3. Pemberton C.J., Johnson M.L., Yandle T.G., and Espiner E.A. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 36 (2000) 355-359
4. Wright S.P., Doughty R.N., Pearl A., et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care. A randomized, controlled trial. J Am Coll Cardiol 42 (2003) 1793-1800
5. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 (2004) 647-654
6. Silver M.A., Maisel A., Yancy C.W., et al. BNP concensus panel. BNP consensus panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10 (2004) 1-30
7. Pfister R., and Schneider C.A. Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives?. Clin Chim Acta 349 (2004) 25-38
8. Lainchbury J.G., Campbell E., Frampton C.M., Yandle T.G., Nicholls M.G., and Richards A.M. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42 (2003) 728-735
9. Davis M., Espiner E., Richards G., et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 343 (1994) 440-444
10. McCullough P.A., Nowak R.M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106 (2002) 416-422
11. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 44 (2004) 1988-1995
12. Foote R.S., Pearlman J.D., Siegel A.H., and Yeo K.T. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol 44 (2004) 1980-1987
13. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
14. Cameron S.J., Green G.B., White C.N., et al. Assessment of BNP and NT-proBNP in emergency department patients presenting with suspected acute coronary syndromes. Clin Chem 39 (2006) 11-18
15. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
16. Galvani M., Ferrini D., and Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur Heart J 6 (2004) 327-333
17. Jernberg T., Stridsberg M., Venge P., and Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 40 (2002) 437-445
18. Omland T., Richards A.M., Wergeland R., and Vik-Mo H. B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. Am J Cardiol 95 (2005) 24-28
19. Kragelund C., Gronning B., Kober L., Hildebrandt P., and Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
20. Heeschen C., Hamm C.W., Mitrovic V., Lantelme N.H., and White H.D. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110 (2004) 3206-3212
21. Ndrepepa G., Braun S., Mehilli J., et al. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol 95 (2005) 553-557
22. Campeau L. Grading of angina pectoris. Circulation 54 (1976) 522-533
23. Sutton T.M., Stewart R.A., Gerber I.L., et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 41 (2003) 2280-2287
24. Talwar S., Downie P.F., Squire I.B., Davies J.E., Barnett D.B., and Ng L.L. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 3 (2001) 15-19
25. Vickery S., Price C.P., John R.I., et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 46 (2005) 610-620
26. WHO Study Group. Diabetes mellitus. Tech Rep Ser 727 (1985) 10-20
27. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 17 (1999) 151-184
28. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, elevation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
29. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
30. Henry W.L., DeMaria A., Gramiak R., et al. Report of the American society of echocardiography committee on nomenclature and standards in two-dimensional echocardiography. Circulation 62 (1980) 212-215
31. Karl J., Borgya A., Gallusser A., et al. Development of a novel, N terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 230 (1999) 177-181
32. Collinson P.O., Barnes S.C., Gaze D.C., et al. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 6 (2004) 365-368
33. Galasko G.I., Lahiri A., Barnes S.C., Collinson P., and Senior R. Eur Heart J 26 (2005) 2269-2276
34. Goetze J.P., Christoffersen C., Perko M., et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 17 (2003) 1105-1107
35. Tateishi J., Masutani M., Ohyanagi M., and Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 23 (2000) 776-780
36. Palazzuoli A., Poldermans D., Capobianco S., et al. Rise and fall of B-type natriuretic peptide levels in patients with coronary artery disease and normal left ventricular function after cardiac revascularization. Coron Artery Dis 17 (2006) 419-423
37. Ten Berg J.M., Kelder J.C., Suttorp M.J., Verheugt F.W.A., and Plokker T. Influence of planned 6-month follow-up angiography on late outcome after percutaneous coronary intervention: a randomized study. J Am Coll Cardiol 38 (2001) 1061-1069
38. Schuhlen H., Kastrati A., Mehilli J., et al. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 147 (2004) 197-199
39. Jernberg T., Stridsberg M., Venge P., and Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratifìcation of patients with chest pain and non-ST segment elevation. J Am Coll Cardiol 40 (2002) 437-445
40. De Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
41. Cowie M.R., Jourdain P., Maisel A., et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24 (2003) 1710-1718
42. Mueller T., Gegenhuber A., Dieplinger B., Poelz W., and Haltmayer M. Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem 51 (2005) 2245-2251
43. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 109 (2004) 3176-3181
44. Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., and Whooley M.A. Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study. Am J Med 116 (2004) 509-516
45. Omland T., Aakvaag A., and Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 76 (1996) 232-237
46. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 341 (2004) 41-48
47. Kragelund C., Gronning B., Omland T., et al. Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease?. Am Heart J 151 (2006) 712.e1-712.e7
48. Conen D., Jander N., Trenk D., Neumann F.-J., and Mueller C. The use of B-type natriuretic peptides in the detection of myocardial ischemia in settings with rapid access to coronary angiography. Int J Cardiol 119 (2007) 416-418
49. Matsubara H., Hirata Y., Yoshimi H., et al. Effects of steroid and thyroid hormones on synthesis of atrial natriuretic peptide by cultured atrial myocytes of rat. Biochem Biophys Res Commun 145 (1987) 336-343